Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.
Bibliographical noteFunding Information:
This investigation was supported by (CNPq; grant # 303479/2018‐3) and (FAPESP, Grant #2013/08135‐2). D.A.P.M. (Grant #2017/23117‐1), J.L.C.‐S. (Grant #2016/23191‐4) and I.W. (Grant #2015/09228‐0) received a fellowship from FAPESP. I.W and D.A.P‐M were sponsored by the Abel Tasman Talent Program of the Graduate School of Medical Sciences of the University of Groningen/University Medical Center Groningen, The Netherlands. Conselho Nacional de Desenvolvimento Científico e Tecnológico Fundação de Amparo à Pesquisa do Estado de São Paulo
Conselho Nacional de Desenvolvimento
Científico e Tecnológico, Grant/Award
Number: 303479/2018-3; Fundação de
Amparo à Pesquisa do Estado de São Paulo,
Grant/Award Number: 2013/08135-2,
2015/09228-0, 2016/23191-4 and 2017/23117-1
© 2022 British Society for Haematology and John Wiley & Sons Ltd.